For research use only. Not for therapeutic Use.
BMS-3（Cat No.:I001288）is a selective inhibitor of the protein kinase C (PKC) pathway, specifically targeting PKCθ. It is being researched for its potential applications in oncology and autoimmune diseases, as PKCθ plays a key role in T-cell activation and proliferation. By inhibiting this pathway, BMS-3 aims to modulate immune responses and reduce tumor growth. Preclinical studies have indicated its promise in enhancing the efficacy of immunotherapies and reducing T-cell mediated inflammation. Ongoing clinical trials are assessing its safety, tolerability, and effectiveness in various treatment settings, focusing on optimizing therapeutic outcomes.
| Catalog Number | I001288 |
| CAS Number | 1338247-30-5 |
| Synonyms | N-[5-[1-(2,6-dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]-2-thiazolyl]-cyclopropanecarboxamide |
| Molecular Formula | C17H12Cl2F2N4OS |
| Purity | ≥95% |
| Target | LIM Kinase (LIMK) |
| Solubility | DMSO: ＞ 30 mg/mL |
| Storage | -20°C |
| IUPAC Name | N-[5-[2-(2,6-dichlorophenyl)-5-(difluoromethyl)pyrazol-3-yl]-1,3-thiazol-2-yl]cyclopropanecarboxamide |
| InChI | InChI=1S/C17H12Cl2F2N4OS/c18-9-2-1-3-10(19)14(9)25-12(6-11(24-25)15(20)21)13-7-22-17(27-13)23-16(26)8-4-5-8/h1-3,6-8,15H,4-5H2,(H,22,23,26) |
| InChIKey | YBGGBHCJSAEIAS-UHFFFAOYSA-N |
| SMILES | C1CC1C(=O)NC2=NC=C(S2)C3=CC(=NN3C4=C(C=CC=C4Cl)Cl)C(F)F |
| Reference | </br>1:[Use of the BMS-3 Radiometer blood gas analyzer for indirect calorimetry]. Dastych M, Kraus P.Cas Lek Cesk. 1987 Jan 30;126(5):150-1. Czech. No abstract available. PMID: 3100047 </br>2:Modification of the radiometer BMS-3 electrode system to improve thermal stability. Bainton CR, Severinghaus JW.Anesthesiology. 1970 Nov;33(5):548-50. No abstract available. PMID: 5478866 |
